| 注册
首页|期刊导航|中国中医药信息杂志|含砷中药复方青黄散安全有效治疗骨髓增生异常综合征方法研究

含砷中药复方青黄散安全有效治疗骨髓增生异常综合征方法研究

邓中阳 王明镜 伊博文 尚晓泓 胡晓梅 方苏 王洪志 郭小青 杨秀鹏 麻柔 许勇钢 杨晓红 赵攀

中国中医药信息杂志2017,Vol.24Issue(10):22-26,5.
中国中医药信息杂志2017,Vol.24Issue(10):22-26,5.DOI:10.3969/j.issn.1005-5304.2017.10.006

含砷中药复方青黄散安全有效治疗骨髓增生异常综合征方法研究

Study on Safe and Effective Clinical Methods for Arsenic-containing Compound Qinghuang Powder in Treatment of Myelodysplastic Syndrome

邓中阳 1王明镜 1伊博文 1尚晓泓 1胡晓梅 1方苏 1王洪志 1郭小青 1杨秀鹏 1麻柔 1许勇钢 1杨晓红 1赵攀1

作者信息

  • 1. 中国中医科学院西苑医院,北京 100091
  • 折叠

摘要

Abstract

Objective To search for application ways for the safe and effective clinical methods of arsenic-containing Compound Qinghuang Powder (Compound QHP) for the treatment of myelodysplastic syndrome (MDS). Methods Totally 200 patients with MDS were included in the study and treated with Compound QHP. After one-month treatment, the 60 patients with the blood arsenic concentrations <20 μg/L were randomly divided into control group and treatment group, with 30 cases in each group. Control group was given stable treatment, while the treatment group was given increased dose of realgar; blood arsenic concentration was detected monthly; realgar 0.1 g was increased each time until blood arsenic concentrations ≥20 μg/L and realgar ≤0.3 g/d. The blood arsenic concentration, clinical efficacy and safety in the two groups were observed. Results Totally 24 cases in each group were included for evaluation finally. The average blood arsenic concentration of treatment group was significantly higher than those of control group (P<0.05). The rate of hematologic improvement was significantly higher in treatment group (54.2%, 13/24) than that in control group (29.2%, 7/24) , with significant difference (P<0.05). The Hb, ANC, and PLT significantly increased in treatment group after treatment (P<0.05). There was no significant difference of incidence rate of adverse reaction observed between treatment group and control group (P>0.05). Conclusion In application of Compound QHP, the blood arsenic concentration can be monitored to adjust the daily dose of realgar, thus to increase the effective blood arsenic concentration, and then improving efficacy without increasing the clinical toxicity.

关键词

骨髓增生异常综合征/雄黄//安全性

Key words

myelodysplastic syndrome/realgar/arsenic/safety

分类

医药卫生

引用本文复制引用

邓中阳,王明镜,伊博文,尚晓泓,胡晓梅,方苏,王洪志,郭小青,杨秀鹏,麻柔,许勇钢,杨晓红,赵攀..含砷中药复方青黄散安全有效治疗骨髓增生异常综合征方法研究[J].中国中医药信息杂志,2017,24(10):22-26,5.

基金项目

国家自然科学基金(81673821) (81673821)

中央级公益性科研院所基本科研业务费专项(ZZ10-016) (ZZ10-016)

北京市科委重点项目(Z141100006014003) (Z141100006014003)

中国中医药信息杂志

OACSCDCSTPCD

1005-5304

访问量0
|
下载量0
段落导航相关论文